Form: 3

Initial statement of beneficial ownership of securities

October 19, 2026

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Shlomi Ruty Ben
(Last) (First) (Middle)
C/O COLLPLANT BIOTECHNOLOGIES LTD.
4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK
(Street)
REHOVOT L3 7670104
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
09/03/2026 		3. Issuer Name and Ticker or Trading Symbol
CollPlant Biotechnologies Ltd [ CLGN ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares 66,501(1) D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Pre-Funded Warrants to Purchase Ordinary Shares 09/03/2026 (2) Ordinary Shares 105,038(1) 0.0001 D
Milestone Pre-Funded Warrants to Purchase Ordinary Shares (3) (3) Ordinary Shares 3,999,446(1)(3) 0.0001 D
Explanation of Responses:
1. Effective as of September 4, 2026, the Issuer effected a 1-for-10 reverse stock split of its Ordinary Shares (the "Reverse Stock Split"). The amount of securities reported on this Form 3 has been adjusted to reflect the Reverse Stock Split.
2. The Pre-Funded Warrants remain exercisable until fully exercised.
3. The Milestone Pre-Funded Warrants become exercisable upon their issuance, subject to the achievement of specified business milestones, and remain exercisable until fully exercised. The Milestone Pre-Funded Warrants are exercisable for up to an aggregate of 3,999,446 ordinary shares, no par value, of the Issuer (the "Ordinary Shares"), with the first tranche, covering 441,683 Ordinary Shares, becoming exercisable upon achievement of the first milestone; the second tranche, covering 1,718,726 Ordinary Shares, becoming exercisable upon achievement of the second milestone; and the third tranche, covering 1,839,037 Ordinary Shares, becoming exercisable upon achievement of the third milestone, in each case subject to the terms and conditions of the Milestone Pre-Funded Warrants.
/s/ Ruty Ben Shlomi 10/19/2026
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.